Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs.
about
Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteinsInterferon protects mice against inhalation anthraxRevisiting the Concept of Targeting Only Bacillus anthracis Toxins as a Treatment for AnthraxProtective antigen as a correlative marker for anthrax in animal modelsEfficacy of Single and Combined Antibiotic Treatments of Anthrax in RabbitsPrioritizing risks and uncertainties from intentional release of selected Category A pathogensNovel and unique diagnostic biomarkers for Bacillus anthracis infection.Anthrax prevention and treatment: utility of therapy combining antibiotic plus vaccine.Combination therapy with antibiotics and anthrax immune globulin intravenous (AIGIV) is potentially more effective than antibiotics alone in rabbit model of inhalational anthrax.Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc regionHuman monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthraxProtection Afforded by Fluoroquinolones in Animal Models of Respiratory Infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis.Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model.Detection of anthrax toxin in the serum of animals infected with Bacillus anthracis by using engineered immunoassaysSearch for Bacillus anthracis potential vaccine candidates by a functional genomic-serologic screen.Evaluation of the metS and murB loci for antibiotic discovery using targeted antisense RNA expression analysis in Bacillus anthracis.Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreakIdentification of in vivo-expressed immunogenic proteins by serological proteome analysis of the Bacillus anthracis secretome.Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerizationAntibiotic selection and resistance issues with fluoroquinolones and doxycycline against bioterrorism agents.Pathology and pathophysiology of inhalational anthrax in a guinea pig model.Involvement of TLR2 in innate response to Bacillus anthracis infection.The solute-binding component of a putative Mn(II) ABC transporter (MntA) is a novel Bacillus anthracis virulence determinant.Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits.Antibiotics cure anthrax in animal models.Treating Anthrax-Induced Meningitis in Rabbits.
P2860
Q24562788-73CC25D5-5C11-44A8-800C-2BDEA7F4A495Q28384715-051896EA-3E10-471C-969D-4D1336CEEAFAQ28384806-543A03C4-FEEA-4E93-AD1F-DBC9E974F043Q28391302-6A6C16B3-5008-449C-B43F-E7B0BB658FF2Q28394063-4B613F3E-92B4-41F3-8BC7-6542A7F0E8E9Q28397363-8FAB0358-E9E2-4206-89B6-21273C1B2C4EQ30157179-94F89757-E209-43CF-A735-C1B099D2283CQ33505445-35629D57-1342-4E25-BA17-2FC6FE223CCBQ34194627-62D7FC9B-5AAB-4CA0-9254-9BD20C155F8CQ34194728-248F1A5D-DE6F-4473-A843-B092FB5E933DQ34334451-4099B406-2101-469D-A17D-7A83955A81A0Q34368520-6103A13D-E832-4855-92D7-A857B2CB8A7AQ34575393-D719EFCC-EF3C-4BCB-8301-3438A73540F6Q34720183-D622C145-5849-4457-93FA-7C963138ED64Q34721071-256777F4-18E6-48A1-AF2E-951CCDC18DD1Q35759041-06090BB0-528F-4DBC-A93B-CE90E554C48EQ35812522-7369238A-7C2D-42CA-ACAA-2FBC433CA696Q35913411-6704D973-13F8-49B1-AFF2-70A6F8C3A8C5Q36007463-5C523351-2879-4C10-A8F5-D038D5EEBAAEQ36408717-92F3EC23-25EC-4DEF-8632-006B33A3B945Q36804713-7E034C67-F49E-4355-9BEF-A4A48FE85BC7Q39886082-E5451BFD-223C-4ADC-BB36-3ACE006273EEQ40384956-A483F867-3E72-42FB-90C5-9261EF186295Q41813154-9025EA1D-21C2-4D0B-BA5E-A2ECEDD55F62Q41890173-214CD3CD-E4CD-4920-875C-648237381A60Q52584720-F8660ABA-A6C4-4571-A530-2BF6A81E0144
P2860
Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Postexposure prophylaxis again ...... anasally infected guinea pigs.
@ast
Postexposure prophylaxis again ...... anasally infected guinea pigs.
@en
Postexposure prophylaxis again ...... anasally infected guinea pigs.
@nl
type
label
Postexposure prophylaxis again ...... anasally infected guinea pigs.
@ast
Postexposure prophylaxis again ...... anasally infected guinea pigs.
@en
Postexposure prophylaxis again ...... anasally infected guinea pigs.
@nl
prefLabel
Postexposure prophylaxis again ...... anasally infected guinea pigs.
@ast
Postexposure prophylaxis again ...... anasally infected guinea pigs.
@en
Postexposure prophylaxis again ...... anasally infected guinea pigs.
@nl
P2093
P2860
P1476
Postexposure prophylaxis again ...... anasally infected guinea pigs.
@en
P2093
Ada Barnea
David Kobiler
Moshe White
Yehoshua Gozes
Zeev Altboum
P2860
P304
P356
10.1128/IAI.70.11.6231-6241.2002
P407
P577
2002-11-01T00:00:00Z